AngioDynamics, Inc. (NASDAQ:ANGO) Files An 8-K Results of Operations and Financial Condition


AngioDynamics, Inc. (NASDAQ:ANGO) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition.

On January 6, 2017, AngioDynamics, Inc. (AngioDynamics or the
Company) issued a press release announcing financial results for
the fiscal second quarter ended November 30, 2016. A copy of the
press release is attached hereto as Exhibit 99.1.

The information set forth in Item 2.02 of this Form 8-K
(including Exhibit 99.1) shall not be deemed filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange
Act, except as shall be expressly set forth by specific reference
in such a filing.

Forward-Looking Statements

This document and its attachments contains forward-looking
statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements regarding
AngioDynamics expected future financial position, results of
operations, cash flows, business strategy, budgets, projected
costs, capital expenditures, products, competitive positions,
growth opportunities, plans and objectives of management for
future operations, as well as statements that include the words
such as expects, reaffirms, intends, anticipates, plans,
believes, seeks, estimates, optimistic, or variations of such
words and similar expressions, are forward-looking statements.
These forward looking statements are not guarantees of future
performance and are subject to risks and uncertainties. Investors
are cautioned that actual events or results may differ from
AngioDynamics expectations. Factors that may affect the actual
results achieved by AngioDynamics include, without limitation,
the ability of AngioDynamics to develop its existing and new
products, technological advances and patents attained by
competitors, infringement of AngioDynamics technology or
assertions that AngioDynamics technology infringes the technology
of third parties, the ability of AngioDynamics to effectively
compete against competitors that have substantially greater
resources, future actions by the FDA or other regulatory
agencies, domestic and foreign health care reforms and government
regulations, results of pending or future clinical trials,
overall economic conditions, the results of on-going litigation,
challenges with respect to third-party distributors or joint
venture partners or collaborators, the results of sales efforts,
the effects of product recalls and product liability claims,
changes in key personnel, the ability of AngioDynamics to execute
on strategic initiatives, the effects of economic, credit and
capital market conditions, general market conditions, market
acceptance, foreign currency exchange rate fluctuations, the
effects on pricing from group purchasing organizations and
competition, the ability of AngioDynamics to integrate purchased
businesses, as well as the risk factors listed from time to time
in AngioDynamics SEC filings, including but not limited to its
Annual Report on Form 10-K for the year ended May 31, 2016 and
its quarterly report on Form 10-Q for the fiscal period ended
August 31, 2016. AngioDynamics does not assume any obligation to
publicly update or revise any forward-looking statements for any

Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.

Exhibit No.



Press Release dated January 6, 2017.

About AngioDynamics, Inc. (NASDAQ:ANGO)

AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company’s Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. The Company’s BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines.

AngioDynamics, Inc. (NASDAQ:ANGO) Recent Trading Information

AngioDynamics, Inc. (NASDAQ:ANGO) closed its last trading session up +0.04 at 16.75 with 714,758 shares trading hands.